Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome

Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome

Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Curēus (Palo Alto, CA) CA), 2023-03, Vol.15 (3), p.e35874
Hauptverfasser: Azad, Farhan, Miranda, Clive J, Amin, Al, Hadwani, Ruhi, Gravina, Matthew
Format: Artikel
Sprache:eng
Schlagworte:
Anemia
Apheresis
Biopsy
Blood platelets
Cancer therapies
Case reports
Chemotherapy
Cholangiocarcinoma
Dehydrogenases
Drug dosages
Edema
Hematology
Hepatitis
Infections
Kidneys
Laboratories
Liver
Metastasis
Monoclonal antibodies
Oncology
Patients
Thrombocytopenia
Vitamin E
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential in this patient population. Complement inhibitors have been used, and our patient improved on eculizumab therapy.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.35874